#ASCO22 – Estudo randomizado fase 2 | Ramucirumabe e pembrolizumabe vs. cuidado padrão no câncer de pulmão de não pequenas células avançado e previamente tratado com imunoterapia.

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A – Journal of Clinical Oncology

Comentário: New drug combination lengthened survival for some with lung cancer – SWOG Cancer Research Network

Comentário no Twitter

📣 #ASCO22 simultaneous pub: Lung-MAP study finds ramucirumab ➕ pembro improved OS in pts w #NSCLC previously treated w/ immune ✔️point inhibitors & chemo. https://t.co/M0zL95ddxD @ReckampK @DrRoyHerbstYale #lcsm

— Journal of Clinical Oncology (@JCO_ASCO) June 3, 2022